Kestra Medical Technologies, Ltd. has partnered with Biobeat Technologies, Ltd. to enhance diagnostic insights for patients using the ASSURE Wearable Cardioverter Defibrillator. The collaboration includes a $5 million investment in Biobeat and aims to integrate their FDA-cleared blood pressure monitoring device into Kestra’s product portfolio. Recent studies show that 72% of patients using the ASSURE WCD are hypertensive, highlighting the importance of managing blood pressure during cardiac recovery. This collaboration is expected to provide valuable clinical data to healthcare providers for better decision-making during patient recovery.

Read more at GlobeNewswire: Kestra Medical Technologies Announces Strategic